LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

5.6 -3.95

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.58

Max

5.76

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+2.68% upside

Turustatistika

By TradingEconomics

Turukapital

245M

747M

Eelmine avamishind

9.55

Eelmine sulgemishind

5.6

Uudiste sentiment

By Acuity

17%

83%

22 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. nov 2025, 16:49 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27. nov 2025, 15:32 UTC

Omandamised, ülevõtmised, äriostud

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27. nov 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27. nov 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. nov 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27. nov 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27. nov 2025, 15:54 UTC

Omandamised, ülevõtmised, äriostud

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27. nov 2025, 15:44 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27. nov 2025, 15:43 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27. nov 2025, 15:42 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27. nov 2025, 15:41 UTC

Omandamised, ülevõtmised, äriostud

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27. nov 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27. nov 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27. nov 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. nov 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27. nov 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27. nov 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27. nov 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27. nov 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27. nov 2025, 11:07 UTC

Tulu

Genting: Positive About Prospects Over Longer Term

27. nov 2025, 11:06 UTC

Tulu

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27. nov 2025, 11:04 UTC

Tulu

Genting: International Travel Demand Expected to Remain Resilient

27. nov 2025, 11:04 UTC

Tulu

Genting: Global Growth Expected to Remain Subdued

27. nov 2025, 11:04 UTC

Tulu

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27. nov 2025, 10:59 UTC

Tulu

Genting Bhd 3Q Net Profit Fell 86% on Year

27. nov 2025, 10:58 UTC

Tulu

Genting Bhd 3Q Rev Rose 14% on Year

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q Net MYR30.3M

27. nov 2025, 10:56 UTC

Tulu

Genting Bhd 3Q EPS MYR0.0079

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

2.68% tõus

12 kuu keskmine prognoos

Keskmine 5.75 USD  2.68%

Kõrge 7.5 USD

Madal 4 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

22 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat